Shenzhen Ausa Pharmed

CompanyChina

Shenzhen Ausa Pharmed develops one asset, in phase 2 (Amlodipine-folic Acid in essential hypertension). Mostly small molecule acting on CACNA1C; based in China.

1
Asset
Furthest stage: Phase 2; 5
Trials: 0
Signals

Pipeline

1

Amlodipine-folic Acid
Combines calcium-channel blockade to lower blood pressure with folate supplementation to reduce homocysteine.
Phase 2, Small molecule, CACNA1C, essential hypertension

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms1
Trials5
Similar companies6